Could a Pre-Transfer clot buster boost stroke recovery?
NCT ID NCT07253181
First seen Jan 08, 2026 · Last updated Jun 14, 2026 · Updated 28 times
Summary
This study looks at whether giving a clot-dissolving drug called Tenecteplase to stroke patients before they are moved to a hospital that can perform a clot-removal procedure improves their recovery. The trial involves 572 adults who had a stroke caused by a large blockage in the front part of the brain and who can be treated within 4.5 to 24 hours after symptoms began. The goal is to see if this early treatment leads to less disability compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Shandong Second Medical University
RECRUITINGWeifang, Shandong, 261031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.